Alzamend Neuro receives Nasdaq delisting notice; hearing scheduled for Oct 12

Alzamend Neuro, Inc.

Nasdaq notified Alzamend on Aug 1, 2023 it failed to regain compliance with $1 bid price rule.
Company ineligible for second 180-day period due to not meeting $5M stockholders' equity initial listing requirement.
Delisting was scheduled for Aug 10, 2023, but stay granted pending appeal to Nasdaq Hearings Panel.
Hearing set for Oct 12, 2023; common stock continues trading under symbol ALZN during stay.
Company has submitted required appeal by Aug 8, 2023 deadline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.